🕵️ Kalaris Therapeutics, Inc. ($KLRS)
SEC insider & ownership activity, last 12 months · CIK 1754068 · every row links its SEC filing
Over the last 12 months insiders sold $13K against $6.2M of open-market buying. Akkaraju Srinivas bought $6.2M in discretionary trades (Dec–May). Srinivas Akkaraju trimmed 56.5% → 54.2%; Samsara Biocapital GP, LLC trimmed 47.9% → 44.9%. No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
1 buyer, $6.2M (2 lots) · 1 seller, $13K (1 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Akkaraju Srinivas | 2 | $6.2M | 0 | – | May 20, 2026 |
| Brett R R Hagen | 0 | – | 1 | $13K | Mar 20, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Srinivas Akkaraju | 54.2% | 13D | May 20, 2026 | filing ↗ | |
| Samsara Biocapital GP, LLC | 44.9% | 13D | May 20, 2026 | filing ↗ | |
| Samsara Biocapital, L.P. | 44.8% | 13D | May 20, 2026 | filing ↗ | |
| Samsara Opportunity Fund, L.P. | 9.3% | 13D | May 20, 2026 | filing ↗ | |
| Samsara Opportunity Fund GP, LLC | 9.3% | 13D | May 20, 2026 | filing ↗ | |
| RTW Investments, LP | 5.7% | 13G | Feb 17, 2026 | filing ↗ | |
| Roderick Wong | 5.7% | 13G | Feb 17, 2026 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Brett R R Hagen | $13K | Mar 20, 2026 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Reg FD disclosure (7.01) | Jul 17, 2026 | filing ↗ |
| Other events (8.01) | Jul 17, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 17, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jul 14, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 14, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jul 3, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 3, 2026 | filing ↗ |
| Earnings (2.02) | May 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 12, 2026 | filing ↗ |
| Officer/director changes (5.02) | Apr 8, 2026 | filing ↗ |
| Earnings (2.02) | Mar 17, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 17, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Mar 9, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 9, 2026 | filing ↗ |
| Material agreement (1.01) | Dec 17, 2025 | filing ↗ |
| Unregistered equity sale (3.02) | Dec 17, 2025 | filing ↗ |
| Other events (8.01) | Dec 17, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Dec 17, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Dec 17, 2025 | filing ↗ |
| Other events (8.01) | Dec 17, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Dec 17, 2025 | filing ↗ |
| Earnings (2.02) | Nov 12, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 12, 2025 | filing ↗ |
| Officer/director changes (5.02) | Oct 28, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Oct 28, 2025 | filing ↗ |
| Earnings (2.02) | Aug 13, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 13, 2025 | filing ↗ |
| Shareholder vote (5.07) | Aug 12, 2025 | filing ↗ |